Dalteparin, a Low Molecular Weight Heparin, as Part of Combination Therapy for Patients with Kawasaki Disease: a Retrospective and Pilot Study
- Conditions
- Kawasaki disease
- Registration Number
- JPRN-UMIN000010349
- Lead Sponsor
- Department of pediatrics and child health, Nihon University School of Medicine
- Brief Summary
A comparison of the first trial with the nationwide survey, showed that the rate of initial administration of IVIG was 80.2% versus 86.0%; the rate of additional IVIG administration was 7.1% versus 14.0% (P < 0.03); the prevalence of CAL in the acute period was 4.8% versus 11.9% (P < 0.01); and the prevalence of cardiovascular sequelae was 0% versus 3.8% (P < 0.05). A comparison of the second trial with the nationwide survey, showed that the rate of initial administration of IVIG was 92.9% versus 89.5%; the rate of additional IVIG administration was 8.9% versus 17.1% (P < 0.02); the prevalence of resistance to IVIG was 3.6% versus 14.9% (P < 0.001); and the prevalence of CAL in the acute period was 2.7% versus 8.6% (P < 0.03).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 238
Not provided
Patients presenting with CAL before the initial treatment were also excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method